Insilico Medicine Nominates Preclinical Candidate Targeting KAT6A for ER+/HER2- Breast Cancer…
Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced that the company's…